

NICORETTE® QUICKMIST MOUTHSPRAY HELPS SMOKERS WISHING TO REDUCE OR QUIT SMOKING AND BECOME NICOTINE FREE¹



NICORETTE® QUICKMIST IS A NICOTINE MOUTHSPRAY, DESIGNED TO AID SMOKING CESSATION¹



Nicorette® QuickMist is a nicotine replacement therapy (NRT) to aid smokers wishing to reduce or quit smoking and as a safer alternative to smoking for smokers and those around them¹

The oral spray formulation of Nicorette® QuickMist allows nicotine to be administered immediately with each spray, and as a result, the **absorption of nicotine is rapid**¹

In clinical trials of Nicorette® QuickMist, nicotine uptake was detected at the first timepoint tested (2 mins), with a maximum concentration reached 13 minutes after administration of a 2mg dose. It has also been shown that Nicorette® QuickMist mouthspray (2x1mg dose) has a fast onset of craving relief¹

It is ideal for use on the go, so patients can act fast to relieve cravings wherever they strike¹



Use 1 or 2 sprays when cigarettes normally would have been smoked or if cravings emerge²
150 sprays in each canister¹



Maximum dose; 4 sprays per hour, with no more than 2 sprays per dose, and 64 sprays in any 24-hour periods¹

Most smokers require 1–2 sprays every 30 minutes or 1 hour¹



Each canister will last **2.3 days** if used at maximum dose¹
As soon as they are able, patients should reduce the number of sprays used until they have stopped completely¹

Nicorette® QuickMist is available in two flavours: Nicorette® QuickMist Freshmint 1mg/spray mouthspray and Nicorette® QuickMist Cool Berry 1mg/spray mouthspray

NICORETTE® QUICKMIST IS SUITABLE FOR A WIDE RANGE OF PATIENTS WHO WANT TO QUIT SMOKING¹

Nicorette® QuickMist can be used by:¹

- Adults and adolescents aged >12 years
- Smokers who want to quit completely, or reduce how much they smoke before quitting
- Pregnant or breastfeeding women*
- All types of smokers, including heavy, moderate or light smokers

*Nicorette® QuickMist is indicated in pregnant or breastfeeding women who cannot quit smoking without pharmacological support¹

NICE guidance advises that a combination of a patch and fast acting NRT is more likely to succeed vs NRT monotherapy alone. Nicorette® QuickMist can also be used in combination with a nicotine patch³


Nicorette® QuickMist is indicated for use in vaping cessation

NICORETTE® QUICKMIST DELIVERS FAST AND EFFECTIVE RELIEF FROM CRAVINGS TO SMOKE⁴

Nicorette® QuickMist is clinically proven to start to relieve cravings in just 60 seconds (2x1mg sprays)⁴

The immediate release of nicotine from Nicorette® QuickMist mouthspray allows for faster onset of craving relief, compared to lozenges which dissolve over 10-20 minutes to release nicotine^{5,6}

Nicorette® QuickMist (2x1mg dose) achieved greater reductions in cravings than either the 2mg or 4mg nicotine lozenge during the first 1, 3 and 5 minutes post-administration⁴



Nicorette® QuickMist is 2.5 times more effective at helping smokers quit compared with placebo at 52 weeks⁷

ABSOLUTE ABSTINENCE RATES FROM SMOKING FOR NICORETTE® QUICKMIST AND PLACEBO UP TO WEEK 52⁷

Help smokers find a path to quit

Time point	Nicotine mouthspray ¹ n(%)	Placebo ¹ n(%)	p value ⁵	Risk ratio (95% CI) ¹
Week 4	101 (31.8)	35 (21.7)	0.022	1.46 (1.05–2.04)
Week 6	83 (26.1)	26 (16.1)	0.014	1.62 (1.09–2.41)
Week 8	78 (24.5)	23 (14.3)	0.009	1.72 (1.12–2.63)
Week 12	64 (20.1)	21 (13.0)	0.055	1.54 (0.98–2.43)
Week 16	57 (17.9)	15 (9.3)	0.013	1.92 (1.13–3.29)
Week 20	53 (16.7)	11 (6.8)	0.003	2.44 (1.31–4.54)
Week 24	50 (15.7)	11 (6.8)	0.006	2.30 (1.23–4.30)
Week 52	44 (13.8)	9 (5.6)	0.007	2.48 (1.24–4.94)

¹:n=318; ²:n=161; ³:p-values were calculated using the Chi-squared test; ⁴: estimated risk ratios/odds ratios and corresponding 95% CIs were calculated using Mantel-Haenszel statistics.

CI, confidence interval, NICE, National Institute for Health and Care Excellence.

For Product Information please see page 2

NICORETTE® QUICKMIST IS NOW INDICATED FOR NICOTINE VAPERS WHO ARE READY TO QUIT¹



NICORETTE® QUICKMIST IS THE FIRST AND ONLY NRT PRODUCT LICENSED TO AID NICOTINE VAPING CESSATION⁸

In Great Britain, **4.7 million adults use e-cigarettes** and 56% of current vapers are ex-smokers⁹

In a UK survey of 1,510 nicotine vapers, 47% wanted to reduce the amount they vaped with 31% wanting to quit vaping entirely¹⁰



150 sprays in each canister¹

Maximum dose; 4 sprays per hour, with no more than 2 sprays per dose, and 64 sprays in any 24-hour periods¹

Each canister will last **2.3 days** if used at maximum dose¹
As soon as they are able, patients should reduce the number of sprays used until they have stopped completely¹


NICORETTE® QUICKMIST IS SUITABLE FOR PATIENTS WHO WANT TO QUIT VAPING NICOTINE¹

NICE guidance recommends discussing quitting with nicotine vapers, when they are ready to do so³

Nicorette® QuickMist can be used by:¹

- Adults and adolescents aged >12 years
- Nicotine vapers who want to quit vaping completely, or reduce how much they vape prior to quitting

Mean urge-to-vape visual analogue scale (VAS) scores were significantly reduced with Nicorette® QuickMist compared to placebo¹¹



NICORETTE® QUICKMIST DELIVERS FAST RELIEF FROM CRAVINGS TO VAPE¹¹

Nicorette® QuickMist starts to relieve cravings to vape in 30 seconds¹¹

Frequency of e-cigarette users achieving a ≥50% reduction in momentary urges-to-vape scores compared to baseline¹¹

Nicorette® Quickmist	Placebo	p value
82.6%	55.1%	<0.001

Comparison vs. placebo. Estimated difference: 27.4%, 95% CI: 15.6–39.2.

CI, confidence interval; NRT, nicotine replacement therapy. NICE, National Institute for Health and Care Excellence.

References:

1. Nicorette® QuickMist 1mg/spray mouthspray SmPC.
2. National Centre For Smoking Cessation And Training. NCSCT Medications. Available at: <https://www.ncsct.co.uk/user/pub/NCSCT%20stop%20smoking%20medications%20quick%20reference%20sheet.pdf> (Accessed December 2022)
3. National Institute for Health and Care Excellence (NICE). Tobacco: preventing uptake, promoting quitting and treating dependence (NG209). Available at: <https://www.nice.org.uk/guidance/ng209> (Accessed December 2022).
4. Hansson A et al. BMJ Open 2012; 2: e001618.

5. Nicorette® Cools 2 mg Lozenge SmPC.
6. Nicorette® Cools 4 mg Lozenge SmPC.
7. Tønnesen P et al. Eur Respir J 2012; 40: 548–554.
8. Electronic Medicines Compendium (EMC). Search results for nicotine. Available at: <https://www.medicines.org.uk/emc/search?q=nicotine> (Accessed December 2022).
9. Action on Smoking and Health. Use of e-cigarettes (vapes) among adults in Great Britain. August 2023. <https://ash.org.uk/uploads/Use-of-e-cigarettes-among-adults-in-Great-Britain-2023.pdf> (Accessed January 2024)
10. Data on file; vapers behaviour and attitudes, 2022.
11. Data on file; QuickMist vaping study, 2022.

NICORETTE® QUICKMIST PRODUCT INFORMATION

Nicorette QuickMist 1mg/spray mouthspray, Nicorette QuickMist Cool Berry 1mg/spray mouthspray & Nicorette QuickMist SmartTrack 1mg/spray mouthspray. **Presentation:** Each 0.07ml contains 1mg nicotine corresponding to 1 mg nicotine/spray dose. **Uses:** Nicorette QuickMist relieves and/or prevents craving and nicotine withdrawal symptoms in nicotine dependence, such as those arising from the use of tobacco or electronic cigarettes. It is indicated to aid quitting or reduction prior to quitting, to assist those who are unwilling or unable to use such products, and as a safer alternative to smoking tobacco for smokers and those around them. **Legal category:** GSL. **PL holder:** McNeil Products Ltd, 50-100 Holmers Farm Way, High Wycombe, HP12 4EG. Information about these products, including adverse reactions, precautions, contraindications, and method of use can be found at: <https://www.medicines.org.uk/emc/search?q=nicorette+quickmist>

NICORETTE® INVISIPATCH & LOZENGE PRODUCT INFORMATION

Nicorette Invisi Patch. **Presentation:** Transdermal patches releasing a nominal of 25mg, 15mg or 10mg of nicotine per 16 hours. Nicorette Cools 2mg Lozenge, Nicorette Cools 4mg Lozenge, Nicorette Fruit 2mg Lozenge. **Presentation:** Each lozenge contains 2mg or 4mg of nicotine. **Uses:** Nicorette Invisi patch/Nicorette Lozenge relieves and/or prevents cravings and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. It is indicated in pregnant and lactating women making a quit attempt. Care should be taken when recommending medicines for use in pregnancy as medicines can cross the placenta and may affect the fetus. Pregnant women are advised to consult their doctor or pharmacist before use. **Legal category:** GSL. **PL holder:** McNeil Products Limited, 50-100 Holmers Farm way, High Wycombe, HP12 4EG. Information about this product, including adverse reactions, precautions, contraindications, and method of use can be found at: Nicorette Invisi Patch: <https://www.medicines.org.uk/emc/search?q=nicorette+invisi> Nicorette Lozenge: <https://www.medicines.org.uk/emc/search?q=Nicorette+lozenge>